The safety of prescription drugs and their adverse effects, however rare, are a source of great debate. 1,2 In an article published in JAMA, Lewis et al. 3 examined the use of pioglitazone and the ...

A type 2 diabetes drug, pioglitazone, may reduce the risk of prostate cancer relapse by targeting the PPARγ protein Prostate cancer patients with diabetes on PPARγ drugs had no relapse during ...

The whole pioglitazone-ban episode has left the health ministry red-faced and insiders conceded that the original move might have been 'ill-informed'. The decision to suspend the sale of the drug ...

Taking the diabetes drug pioglitazone, better known by the brand name Actos, doubles the risk of developing bladder cancer, Canadian researchers have found. In absolute terms, however, the risk ...

Actos is available as the generic drug pioglitazone. Generics usually cost less than brand-name drugs. Talk with your doctor if you’d like to know about taking generic pioglitazone.

Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, analyses that included nearly 200,000 patients found no statistically ...

We randomly assigned 247 adults with nonalcoholic steatohepatitis and without diabetes to receive pioglitazone at a dose of 30 mg daily (80 subjects), vitamin E at a dose of 800 IU daily (84 ...

Reason for posting: Pioglitazone is an oral hypoglycemic agent widely used as monotherapy or combination therapy for type 2 diabetes mellitus. However, a recent analysis by the drug's manufacturer of ...

Compared with other antidiabetic drugs, pioglitazone was associated with a 63% increased risk of bladder cancer (121 cases per 100,000 person-years vs 89 cases per 100,000 person-years; hazard ...

Compared with pioglitazone, rosiglitazone produces unfavorable changes in plasma LDL-C, lipoprotein particles, and triglycerides. The 2 drugs are structurally different and may have different ...

Chennai, May 24 -- Highlights: * A type 2 diabetes drug, pioglitazone, may reduce the risk of prostate cancer relapse by targeting the PPAR (and) #947; protein ...